LGALS3 and prostate cancer: Galectin-3 showed significantly lower protein levels in urine from prostate-cancer patients with relapse compared to urine from patients without relapse (median control urine = 0.27 pmol/mg, median in urine of prostate-cancer patients without relapse = 0.48 pmol/mg; median in urine of prostate-cancer patients with relapse = 0.13 pmol/mg; P = 0.017, Figure 8).